Mode
Text Size
Log in / Sign up
N/A N=600 Randomized Triple-blind Supportive Care

Diabetes Outcomes and Unmet Resources

Diabetes

Enrolled (actual)
600
Serious AEs
41.3%
Results posted
May 2024
Primary outcome: Primary: Change in HbA1c as Measured by an HbA1c Machine — 0.07; -0.10 percentage of average glucose 3 months

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CareAvenue (Behavioral); Guest Assistance Program (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Michigan
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in HbA1c as Measured by an HbA1c Machine
0.07; -0.10
SECONDARY
Change in Systolic Blood Pressure as Measured an Automated Blood Pressure Machine
-4.00; -6.00
SECONDARY
Change in Cost-Related Non-Adherence Behaviors With Prescribed Treatment Regimens Related to Diabetes as Measured by Participant Questionnaire
-0.45; -0.91
SECONDARY
Change in Cost-Related Non-Adherence Behaviors With Prescribed Treatment Regimens Related to Other Conditions Being Managed as Measured by Participant Questionnaire
-0.07; -0.06
SECONDARY
Change in Perceived Financial Burden as Measured by the Comprehensive Score for Financial Toxicity (COST) - Functional Assessment of Chronic Illness Therapy (FACIT)
2.01; 2.74
SECONDARY
Change in Unmet Social Risk Factors as Measured by 20 Items in Participant Questionnaire
-1.05; -1.48
SECONDARY
Change in Unmet Social Risk Factors as Measured by Participant Questionnaire
-0.26; -0.27

Summary

This study will refine and test the effectiveness of CareAvenue, an automated e-health tool that informs and activates patients with uncontrolled diabetes to take steps in accessing resources and engaging in self-care. Our central hypothesis is that activating patients with uncontrolled diabetes and linking them to resources to address financial burden and unmet social risk factors will improve both intermediate outcomes and measures of disease control above and beyond existing services, especially for high need patients.

Eligibility Criteria

Inclusion Criteria

  • Be 18-75 years of age
  • Be diagnosed with type 1 or type 2 diabetes with prescribed anti-hyperglycemic medication
  • Have a most recent hemoglobin A1c(HbA1c) level within the past 6 months of ≥7.5% for individuals ≤70 years and >8.0% for individuals between 70-75 years in age
  • Have access to a telephone that can receive and send text messages
  • Not participating in another diabetes intervention research study

Exclusion Criteria

  • Significant cognitive impairment precluding individuals from completing the study as evidenced by ability to complete study intake procedures.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03950973). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search